×
About 8,340 results

ALLMedicine™ Myelodysplastic Syndrome Center

Research & Reviews  2,711 results

Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: ...
https://doi.org/10.1080/17474086.2022.2077721
Expert Review of Hematology; Finelli C, Parisi S et. al.

May 14th, 2022 - Anemia is often present in mostly elderly patients with myelodysplastic syndromes (MDS), and is associated with a poorer outcome. Although Red blood cell (RBC) transfusions are the most immediate treatment, waiting for the response to disease-spec...

Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
https://doi.org/10.1002/ajh.26589
American Journal of Hematology; Shah MV, Chhetri R et. al.

May 14th, 2022 - Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax, represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax h...

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
https://clinicaltrials.gov/ct2/show/NCT01861106

May 13th, 2022 - Background: Genetic and sporadic mutations on one allele of the GATA2 gene lead to a syndrome termed MonoMAC. MonoMAC is characterized by: 1) infections with Mycobacterium avium complex (MAC) and other opportunistic infections, 2) deficiency of mo...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Study to Evaluate CCS1477 in Haematological Malignancies
https://clinicaltrials.gov/ct2/show/NCT04068597

May 13th, 2022 - A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

see more →

Guidelines  2 results

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.

Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellula...
https://doi.org/10.3324/haematol.13755
Haematologica Bennett JM, Orazi A

Jan 16th, 2009 - Members of the French-American-British Cooperative Leukemia Working Group met to review cases of aplastic anemia, hypocellular myelodysplastic syndrome and hypocellular acute myeloid leukemia. Criteria were proposed and modified following three wo...

see more →

Drugs  33 results see all →

Clinicaltrials.gov  256 results

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
https://clinicaltrials.gov/ct2/show/NCT01861106

May 13th, 2022 - Background: Genetic and sporadic mutations on one allele of the GATA2 gene lead to a syndrome termed MonoMAC. MonoMAC is characterized by: 1) infections with Mycobacterium avium complex (MAC) and other opportunistic infections, 2) deficiency of mo...

Study to Evaluate CCS1477 in Haematological Malignancies
https://clinicaltrials.gov/ct2/show/NCT04068597

May 13th, 2022 - A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Eltrombopag for People With Fanconi Anemia
https://clinicaltrials.gov/ct2/show/NCT03206086

May 13th, 2022 - Fanconi anemia (FA) is a rare genetic disease that often presents as a bone marrow failure (BMF) syndrome but also can affect any other organ. Etiologically, loss of function mutations in more than 21 different gene members of the FA core complex ...

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
https://clinicaltrials.gov/ct2/show/NCT05342584

May 6th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability and to determine the dose-limiting toxicity and the maximum tolerated dose MTD of the combination of daunorubicin, cytarabine (7+3) + venetoclax for patients with acute myeloid leukemi...

see more →

News  332 results

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-placed-on-studies-evaluating-magrolimab-in-mds-and-aml

May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...

FDA Grants Fast Track Status to PRGN-3006 for Relapsed/Refractory AML
https://www.onclive.com/view/fda-grants-fast-track-status-to-prgn-3006-for-relapsed-refractory-aml

May 2nd, 2022 - The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia (AML), according to an announcement fro...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma

Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...

COVID Vaccine Response Varies by Blood Cancer Type, Treatment
https://www.medscape.com/viewarticle/972428

Apr 20th, 2022 - The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways The seropositivity rate after a second COVID-19 vaccine dose was 95% among patients with acute myeloid leukemia (AML) or...

see more →

Patient Education  2 results see all →